KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Rating of “Hold” from Analysts

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have been assigned an average rating of “Hold” from the nine ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $30.60.

KALV has been the topic of several research analyst reports. Leerink Partners lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Citizens Jmp lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Needham & Company LLC downgraded KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 30th. HC Wainwright lowered KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the company from $37.00 to $27.00 in a research note on Friday, May 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, April 21st.

KalVista Pharmaceuticals Price Performance

KALV opened at $27.00 on Monday. The business has a 50 day moving average of $24.16 and a 200-day moving average of $18.83. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -7.80 and a beta of -0.12. The company has a current ratio of 5.17, a quick ratio of 5.10 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals has a 1-year low of $9.83 and a 1-year high of $27.00.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The company had revenue of $40.86 million for the quarter, compared to analyst estimates of $39.03 million. As a group, sell-side analysts anticipate that KalVista Pharmaceuticals will post -1.19 earnings per share for the current year.

Insider Transactions at KalVista Pharmaceuticals

In related news, insider Nicole Sweeny sold 1,489 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $26.78, for a total value of $39,875.42. Following the completion of the transaction, the insider directly owned 59,291 shares of the company’s stock, valued at $1,587,812.98. This trade represents a 2.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Paul K. Audhya sold 2,239 shares of KalVista Pharmaceuticals stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $26.78, for a total transaction of $59,960.42. Following the sale, the insider owned 150,260 shares in the company, valued at $4,023,962.80. This represents a 1.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 254,602 shares of company stock valued at $4,656,670. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Seven Fleet Capital Management LP boosted its position in shares of KalVista Pharmaceuticals by 165.4% during the 1st quarter. Seven Fleet Capital Management LP now owns 128,487 shares of the specialty pharmaceutical company’s stock valued at $2,586,000 after acquiring an additional 80,075 shares in the last quarter. Parallel Advisors LLC lifted its stake in KalVista Pharmaceuticals by 45.8% during the first quarter. Parallel Advisors LLC now owns 1,876 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 589 shares during the period. Optiver Holding B.V. boosted its holdings in KalVista Pharmaceuticals by 2,981.2% during the first quarter. Optiver Holding B.V. now owns 4,591 shares of the specialty pharmaceutical company’s stock valued at $92,000 after purchasing an additional 4,442 shares in the last quarter. Bank of America Corp DE grew its stake in shares of KalVista Pharmaceuticals by 42.5% in the 1st quarter. Bank of America Corp DE now owns 555,628 shares of the specialty pharmaceutical company’s stock valued at $11,185,000 after purchasing an additional 165,815 shares during the period. Finally, Royal Bank of Canada raised its holdings in shares of KalVista Pharmaceuticals by 137.0% in the 1st quarter. Royal Bank of Canada now owns 2,917 shares of the specialty pharmaceutical company’s stock worth $59,000 after buying an additional 1,686 shares in the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.